Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)

被引：0
|
作者：
Beal, K. [1 ]
Omuro, A. [1 ]
Karimi, S. [1 ]
Correa, D. [1 ]
Chan, T. A. [1 ]
DeAngelis, L. M. [1 ]
Yamada, Y. [1 ]
Abrey, L. E. [1 ]
Gutin, P. H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [31] SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
    Cloughesy, Tim
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Revil, Cedric
    Abrey, Lauren
    Chinot, Olivier L.
    NEURO-ONCOLOGY, 2014, 16
  • [32] Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
    Schiff, David
    Huse, Jason
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16 (06) : 769 - 769
  • [33] Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Hoang-Xuan, Khe
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Abrey, Lauren
    Cloughesy, Timothy
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08): : 709 - 722
  • [34] A phase II trial of lithium, bevacizumab, temozolomide, and radiation for newly diagnosed glioblastomas (GBM).
    Narayana, Ashwatha
    Tam, Moses M.
    Gruber, Deborah Beth
    Golfinos, John
    Parker, Erik
    Zagzag, David
    Gruber, Michael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme
    Ammirati, Mario
    Chotai, Silky
    Newton, Herbert
    Lamki, Tarig
    Wei, Lai
    Grecula, John
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (04) : 633 - 637
  • [36] Radiotherapy, temozolomide, and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma multiforme: Preliminary results front an ongoing phase II trial
    Kirkpatrick, J. P.
    Desjardins, A.
    Reardon, D. A.
    Vredenburgh, J. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S209 - S209
  • [37] Postmortem evaluation of end-organ toxicity in patients with glioblastoma (GBM) treated with temozolomide (TMZ) and bevacizumab (BEV).
    Zhu, J.
    Tian, X. J.
    Linendoll, N.
    Pfannl, R.
    Pilichowska, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
    Toshihide Tanaka
    Ryota Tamura
    Jun Takei
    Yukina Morimoto
    Akihiko Teshigawara
    Yohei Yamamoto
    Ryotaro Imai
    Yuki Kuranari
    Kyoichi Tohmoto
    Yuzuru Hasegawa
    Yasuharu Akasaki
    Yuichi Murayama
    Keisuke Miyake
    Hikaru Sasaki
    Journal of Neuro-Oncology, 2024, 166 : 557 - 567
  • [39] An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
    Tanaka, Toshihide
    Tamura, Ryota
    Takei, Jun
    Morimoto, Yukina
    Teshigawara, Akihiko
    Yamamoto, Yohei
    Imai, Ryotaro
    Kuranari, Yuki
    Tohmoto, Kyoichi
    Hasegawa, Yuzuru
    Akasaki, Yasuharu
    Murayama, Yuichi
    Miyake, Keisuke
    Sasaki, Hikaru
    JOURNAL OF NEURO-ONCOLOGY, 2024, 166 (03) : 557 - 567
  • [40] Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
    Reddy, Krishna
    Damek, Denise
    Gaspar, Laurie E.
    Ney, Douglas
    Waziri, Allen
    Lillehei, Kevin
    Stuhr, Kelly
    Kavanagh, Brian D.
    Chen, Changhu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : 655 - 660
12345